Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Donna Lamb is using her medical education perspective in her latest leadership role, from her job as a critical care nurse to working with doctors to connect nurses who are checking patients on the job during the outbreak.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.
Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.
IgA Nephropathy in 2025: Year in Review
1.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
2.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
3.
For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.
4.
Prior authorizations draining time, energy from many cancer patients
5.
Could the Prostate Cancer Story of Francis Collins Dissuade Men from Active Surveillance?
1.
The Immune Revolution: Neoantigen Vaccines and the Dawn of Personalized Cancer Therapy in 2025
2.
The Life-Saving Powers of Anemia: How to Combat the Disease.
3.
Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome
4.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
5.
Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge